

# Sujata Patil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11329535/publications.pdf>

Version: 2024-02-01

165  
papers

9,970  
citations

36691

53  
h-index

46524

93  
g-index

167  
all docs

167  
docs citations

167  
times ranked

13965  
citing authors

#	ARTICLE	IF	CITATIONS
1	Logistic Regression in Clinical Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 271-277.	0.4	30
2	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	1.9	12
3	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
4	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	2.3	9
5	Vulnerabilities in workplace features for essential workers with breast cancer: Implications for the COVID-19 pandemic. <i>Work</i> , 2022, 71, 815-823.	0.6	2
6	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â trastuzumab in patients with breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2022, 8, 50.	2.3	17
7	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	0.8	292
8	Predictors of operative difficulty in robotic low anterior resection for rectal cancer. <i>Colorectal Disease</i> , 2022, 24, 1318-1324.	0.7	2
9	Lymphedema therapy referral is associated with improved understanding of lymphedema prevention among breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12069-12069.	0.8	0
10	Primary Tumor-Related Complications and Salvage Outcomes in Patients with Metastatic Rectal Cancer and an Untreated Primary Tumor. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 45-52.	0.7	7
11	Comparative analysis of the Memorial Sloan Kettering Bowel Function Instrument and the Low Anterior Resection Syndrome Questionnaire for assessment of bowel dysfunction in rectal cancer patients after low anterior resection. <i>Colorectal Disease</i> , 2021, 23, 451-460.	0.7	16
12	Interpreting the RAPIDO trial: factors to consider. <i>Lancet Oncology</i> , The, 2021, 22, e87-e88.	5.1	1
13	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.	1.9	8
14	Comprehensive Molecular Characterization and Response to Therapy in Fumarate HydrataseâDeficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
15	Endoscopic Feature and Response Reproducibility in Tumor Assessment after Neoadjuvant Therapy for Rectal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 5205-5223.	0.7	11
16	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i>-Mutated HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3867-3875.	3.2	15
17	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1274-1281.	2.1	6
18	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1463-1470.	0.7	22
20	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 432-438.	2.3	19
21	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
22	Comparing outcomes of robotic <i>versus</i> open mesorectal excision for rectal cancer. <i>BJs Open</i> , 2021, 5, .	0.7	6
23	In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059.		5
24	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.	5.1	121
25	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in 20011-Eligible Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1617-1624.	0.7	20
26	Early Trastuzumab Interruption and Recurrence-Free Survival in <i>ERBB2</i> -Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1971.	3.4	20
27	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	2.1	3
28	Use of patient-reported controls for secular trends to study disparities in cancer-related job loss. <i>Journal of Cancer Survivorship</i> , 2020, 15, 685-695.	1.5	1
29	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	2.0	22
30	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	0.8	11
31	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	2.9	23
32	Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Case-Control Study. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 897-902.	0.7	41
33	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
34	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
35	The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. <i>Nature Communications</i> , 2020, 11, 319.	5.8	46
36	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	5.7	96

#	ARTICLE	IF	CITATIONS
37	Intracorporeal Anastomoses in Minimally Invasive Right Colectomies Are Associated With Fewer Incisional Hernias and Shorter Length of Stay. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 685-692.	0.7	40
38	Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms. <i>JAMA Network Open</i> , 2020, 3, e200681.	2.8	54
39	Measuring Tumor Epichaperome Expression Using [ <sup>124</sup> I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1414-1424.	1.5	13
40	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , 2019, 24, e646-e652.	1.9	5
41	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	15.2	320
42	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
43	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	0.8	17
44	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 61-66.	1.1	42
45	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3784-3792.	3.2	41
46	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
47	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 794-799.	0.9	2
48	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2019, 2, e1916211.	2.8	7
49	Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	1.5	7
50	Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 800-807.	0.9	21
51	Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. <i>Clinical Breast Cancer</i> , 2018, 18, 353-361.	1.1	16
52	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	1.1	37
53	Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1912-1920.	0.7	37
54	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. <i>Cancer</i> , 2018, 124, 46-54.	2.0	37

#	ARTICLE	IF	CITATIONS
55	Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 1146-1155.	0.7	115
56	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	3.4	132
57	Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1492-1498.	0.7	47
58	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. <i>Journal of Bone Oncology</i> , 2017, 7, 32-37.	1.0	21
59	Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. <i>Health Affairs</i> , 2017, 36, 274-281.	2.5	75
60	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. <i>Oncologist</i> , 2017, 22, 139-143.	1.9	27
61	Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2182-2188.	0.7	30
62	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
63	Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 2556-2562.	0.7	45
64	Work Experiences of Patients Receiving Palliative Care at a Comprehensive Cancer Center: Exploratory Analysis. <i>Journal of Palliative Medicine</i> , 2017, 20, 770-773.	0.6	10
65	Are there patients with T1 to T2, lymph node-negative breast cancer who are at high risk for locoregional disease recurrence?. <i>Cancer</i> , 2017, 123, 2626-2633.	2.0	16
66	Single Nucleotide Polymorphism TGF $\beta$ 1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 924-930.	0.4	10
67	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3888-3895.	0.7	13
68	Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. <i>Annals of Surgical Oncology</i> , 2017, 24, 2889-2897.	0.7	28
69	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. <i>Annals of Surgery</i> , 2017, 266, 457-462.	2.1	90
70	Breast carcinoma with an Oncotype Dx recurrence score $\leq 18$ : Rate of distant metastases in a large series with clinical follow-up. <i>Cancer</i> , 2017, 123, 131-137.	2.0	16
71	Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. <i>Clinical Breast Cancer</i> , 2017, 17, 23-28.	1.1	91
72	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 89.	2.2	45

#	ARTICLE	IF	CITATIONS
73	A Randomized Prospective Comparison of Patient-Assessed Satisfaction and Clinical Outcomes with Radioactive Seed Localization versus Wire Localization. <i>Breast Journal</i> , 2016, 22, 151-157.	0.4	65
74	Twenty-one "gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. <i>Cancer</i> , 2016, 122, 1178-1184.	2.0	42
75	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2548-2555.	0.7	70
76	Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2016, 21, 418-424.	1.9	46
77	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	0.8	31
78	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	0.7	232
79	Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. <i>Annals of Surgical Oncology</i> , 2016, 23, 2816-2824.	0.7	38
80	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 3481-3486.	0.7	25
81	Long-Term Renal Outcomes after Cisplatin Treatment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1173-1179.	2.2	155
82	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	0.8	69
83	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	13.7	233
84	Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer. <i>European Journal of Radiology</i> , 2016, 85, 1651-1658.	1.2	42
85	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 835-844.	1.6	138
86	Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 487-493.	1.1	13
87	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. <i>Annals of Surgical Oncology</i> , 2016, 23, 4253-4261.	0.7	40
88	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.3	9
89	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	1.9	84
90	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?. Journal of the American College of Surgeons, 2016, 222, 138-145.	0.2	68
92	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer, 2016, 16, 87-94.	1.1	1
93	Fertility Preservation for the Young Breast Cancer Patient. Annals of Surgical Oncology, 2016, 23, 1530-1536.	0.7	35
94	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical Breast Cancer, 2016, 16, 276-283.	1.1	11
95	Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. Annals of Surgical Oncology, 2016, 23, 471-476.	0.7	13
96	Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. Annals of Surgery, 2015, 262, 623-631.	2.1	94
97	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2015, 33, 442-447.	0.8	75
98	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical Genitourinary Cancer, 2015, 13, 453-460.	0.9	5
99	Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecologic Oncology, 2015, 138, 566-572.	0.6	34
100	Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 957-966.	5.1	524
101	Does Endoscopic Ultrasound Improve Detection of Locally Recurrent Anal Squamous-Cell Cancer?. Diseases of the Colon and Rectum, 2015, 58, 193-198.	0.7	7
102	Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2015, 22, 3273-3281.	0.7	46
103	Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. Journal of Clinical Oncology, 2015, 33, 3945-3952.	0.8	153
104	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. Clinical Genitourinary Cancer, 2015, 13, 59-66.	0.9	32
105	Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years.. Journal of Clinical Oncology, 2015, 33, 32-32.	0.8	1
106	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE, 2014, 9, e114900.	1.1	77
107	Local Relapse After Breast-Conserving Therapy for Ductal Carcinoma In Situ. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overl	1.0	49
108	Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation. Annals of Surgical Oncology, 2014, 21, 1552-1560.	0.7	50

#	ARTICLE	IF	CITATIONS
109	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 22-27.	0.7	99
110	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 154-160.	1.1	91
111	Intravoxel incoherent motion diffusion-weighted MRI at 3.0 T differentiates malignant breast lesions from benign lesions and breast parenchyma. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 813-823.	1.9	95
112	Brain metastases in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 173-183.	1.1	8
113	Estrogen Receptor, Progesterone Receptor, and HER2 Status Predict Lymphovascular Invasion and Lymph Node Involvement. <i>Annals of Surgical Oncology</i> , 2014, 21, 3780-3786.	0.7	71
114	Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 407-416.	1.1	56
115	Is there a role for routine screening MRI in women with LCIS?. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 445-453.	1.1	53
116	Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 297-302.	0.9	46
117	Should Breast Density Influence Patient Selection for Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2013, 20, 600-606.	0.7	17
118	Blurry Boundaries: Do Epithelial Borderline Lesions of the Breast and Ductal Carcinoma In Situ Have Similar Rates of Subsequent Invasive Cancer?. <i>Annals of Surgical Oncology</i> , 2013, 20, 1302-1310.	0.7	7
119	Selection Criteria for Postmastectomy Radiotherapy in T1-T2 Tumors with 1 to 3 Positive Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2013, 20, 3169-3174.	0.7	77
120	Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. <i>Cancer Medicine</i> , 2013, 2, 725-733.	1.3	54
121	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581.	2.0	30
122	Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. <i>Cancer</i> , 2013, 119, 3943-3951.	2.0	18
123	Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC). <i>Journal of Clinical Oncology</i> , 2013, 31, 144-144.	0.8	1
124	Validation of a Nomogram for Predicting Risk of Local Recurrence for Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2012, 30, 3143-3144.	0.8	7
125	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> , 2012, 118, 5454-5462.	2.0	55
126	Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 93-102.	1.1	34



#	ARTICLE	IF	CITATIONS
127	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6784-6791.	3.2	176
128	Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. <i>Breast Journal</i> , 2012, 18, 345-350.	0.4	29
129	Phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876.	2.0	109
130	Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> , 2012, 118, 1982-1988.	2.0	80
131	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986.	2.0	50
132	Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. <i>Cancer</i> , 2012, 118, 1664-1674.	2.0	81
133	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 111-116.	1.1	21
134	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 335-340.	1.2	79
135	Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i). <i>Journal of Clinical Oncology</i> , 2012, 30, 10618-10618.	0.8	3
136	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	0.6	91
137	PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 635-643.	1.1	49
138	Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. <i>Cancer</i> , 2011, 117, 4125-4131.	2.0	16
139	Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. <i>Cancer</i> , 2011, 117, 5461-5468.	2.0	77
140	Reply to S. Stenning et al and J. Lipshitz. <i>Journal of Clinical Oncology</i> , 2011, 29, 4211-4212.	0.8	0
141	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. <i>Clinical Cancer Research</i> , 2011, 17, 3490-3499.	3.2	131
142	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. <i>Clinical Cancer Research</i> , 2011, 17, 5132-5139.	3.2	396
143	Carboplatin in Clinical Stage I Seminoma: Too Much and Too Little at the Same Time. <i>Journal of Clinical Oncology</i> , 2011, 29, 949-952.	0.8	23
144	Reply to C. Mazouni et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e45-e46.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Targeted Oligonucleotide Array Assessment of Genomic Copy Number Alterations for Risk Stratification in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1773-1773.	0.6	0
146	The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy. <i>Annals of Surgery</i> , 2010, 251, 583-591.	2.1	40
147	Impact of Breast Density on the Presenting Features of Malignancy. <i>Annals of Surgical Oncology</i> , 2010, 17, 211-218.	0.7	141
148	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528.	1.2	66
149	Stage migration and increasing proportion of favorable prognosis metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 347-354.	2.0	46
150	Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3154-3159.	0.8	121
151	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713.	0.8	192
152	Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. <i>Journal of Clinical Oncology</i> , 2010, 28, 2982-2988.	0.8	40
153	Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2010, 28, 3762-3769.	0.8	283
154	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5049-5059.	3.2	338
155	Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1432-1439.	0.8	298
156	Distress in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4346-4351.	0.8	116
157	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5240-5247.	0.8	70
158	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. <i>Cancer</i> , 2009, 115, 1203-1214.	2.0	19
159	Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. <i>Journal of Clinical Oncology</i> , 2009, 27, 3379-3384.	0.8	370
160	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 147-153.	0.7	100
161	Phase II Trial of Pegylated Interferon- $\beta$ in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30.	0.9	20
162	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600.	2.0	6

#	ARTICLE	IF	CITATIONS
163	Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1797-1802.	0.8	60
164	Identifying Vulnerable Older Adults with Cancer: Integrating Geriatric Assessment into Oncology Practice. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1604-1608.	1.3	131
165	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490.	1.2	21